David O’Toole
Chief Financial OfficerMr. David O’Toole is Chief Financial Officer of AVITA Medical, Inc. from June 15, 2023. He is an accomplished financial executive with years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public companies. He will play a critical role in executing the company's strategic growth initiatives and in leading the financial organization. He most recently served as CFO of Opiant Pharmaceuticals, a biopharmaceutical company developing treatments for addiction and drug overdose, which was acquired by Indivior PLC in March of 2023. Prior to that, he served as CFO of Soleno Therapeutics, a company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Prior to Soleno, he held the role of CFO for three publicly traded life sciences companies where he built and led high-performance teams. Prior to his CFO experience, he spent years in public accounting, including 16 years with Deloitte & Touche. He holds a Bachelor of Science in accounting from the University of Arizona and is a Certified Public Accountant (non-active).
Positions
- Company NameAVITA Medical, Inc.Stock CodeRCELPositionChief Financial OfficerColleagues
- CGCary G. VancePresident, CEO & Executive Director
- JSJan Stern ReedIndependent Chairman of the Board
- NLNicole Linda KelseyChief Legal & Compliance Officer & Corporate Secretary
- NDNiraj DoshiSenior Vice President of Global Operations
- KBKatie BushSenior Vice President of Scientific & Medical Affairs
- RERobert E. McNamaraIndependent Non-Executive Director
- MEMichael Eric TarnoffIndependent Non-Executive Director
- FMFiona Melanie WoodFounder and Member of Clinical Advisory Board
